Inmune Bio Inc. (INMB)
NASDAQ (CM) NASDAQ (CM) Primary 
INmune Bio Inc. (INMB) Q1 2026 Earnings Call Prepared Remarks Transcript
INmune Bio Inc. (INMB) Q1 2026 Earnings Call Prepared Remarks Transcript
INmune Bio Inc. (INMB) Q4 2025 Earnings Call Transcript
INmune Bio Inc. (INMB) Q4 2025 Earnings Call Transcript
INmune Bio Inc. (INMB) Discusses XPro1595 Phase II MINDFuL Results and Registrational Strategy in Alzheimer's Disease Transcript
INmune Bio Inc. (INMB) Discusses XPro1595 Phase II MINDFuL Results and Registrational Strategy in Alzheimer's Disease Transcript
INmune Bio Inc. (INMB) Discusses MissionEB Phase III Trial and CORDStrom as a Disease-Modifying Therapy for RDEB Transcript
INmune Bio Inc. (INMB) Discusses MissionEB Phase III Trial and CORDStrom as a Disease-Modifying Therapy for RDEB Transcript
INmune Bio (INMB) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
INmune Bio (INMB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
INmune Bio, Inc. (INMB) Q3 2025 Earnings Call Transcript
INmune Bio, Inc. ( INMB ) Q3 2025 Earnings Call October 30, 2025 4:30 PM EDT Company Participants Daniel Carlson David Moss - President, CEO, Treasurer, Secretary & Director Mark Lowdell - Chief Scientific Officer & Chief Manufacturing Officer CJ Barnum Cory Ellspermann - Interim Chief Financial Officer Conference Call Participants Denis Reznik - Raymond James Ltd., Research Division Jason Mccarthy - Maxim Group LLC, Research Division Presentation Operator " Daniel Carlson " David Moss President, CEO, Treasurer, Secretary & Director " Mark Lowdell Chief Scientific Officer & Chief Manufacturing Officer " CJ Barnum " Cory Ellspermann Interim Chief Financial Officer " Denis Reznik Raymond James Ltd.
INmune Bio, Inc. (INMB) Q2 2025 Earnings Call Transcript
INmune Bio, Inc. (NASDAQ:INMB ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Christopher Barnum - Corporate Participant Daniel Carlson - Corporate Participant David J. Moss - CFO, Treasurer & Secretary Mark William Lowdell - Chief Scientific Officer & Chief Manufacturing Officer Raymond Joseph Tesi - Co-Founder, President, CEO, Chief Medical Officer & Chairman Conference Call Participants Boris Tolkachev - Freedom Broker, Research Division Denis Reznik - Raymond James Ltd.
INmune Bio: Thinking Through XPro's MINDFuL Data In Early Alzheimer's
INmune Bio's XPro missed its Phase II primary endpoint, but subgroup data and safety profile suggest potential for targeted Alzheimer's patients with neuroinflammation. Despite the setback, I see significant upside from XPro and CORDStrom, with blockbuster potential if approved, given INMB's tiny current market cap. Risks include uncertain XPro efficacy, need for more capital, and dilution; I maintain a 2/5 conviction rating and keep INMB in my speculative portfolio.
INmune Bio shares tumble as Alzheimer's drug falls short in mid-stage trial
INmune Bio Inc (NASDAQ:INMB) shares plummeted almost 60% following disappointing results from a Phase 2 clinical trial of its experimental Alzheimer's drug, XPro. The drug failed to meet the primary cognitive endpoint in the overall intent-to-treat population, meaning it did not significantly improve cognitive function over six months compared to placebo in early Alzheimer's patients.
INmune Bio: Finding Pay Dirt In Alzheimer's?
INmune Bio is working on a drug for Alzheimer's, with a critical phase 2 readout to be announced. It is unclear whether this will be positive or negative. Other potential drug candidates could help pick up the slack if MINDFuL is a dud.
INmune Bio: Imminent Phase 2 Alzheimer's Readout Of Unique Asset Presents Interesting Speculative Opportunity
INmune Bio offers a high-risk, high-reward opportunity ahead of its Phase 2 Alzheimer's readout. Lead asset XPro1595's mechanism of selectively targeting soluble TNF (sTNF) has strong preclinical, mechanistic, and limited but encouraging Phase 1b data. If XPro1595 delivers positive results, it could validate a new approach in Alzheimer's and other inflammatory diseases, but the investment remains speculative due to clinical and market risks.
INmune Bio: XPro Trial Readout In Alzheimer's Disease Offers Big Opportunity
I rate INmune Bio, Inc. a speculative Strong Buy for high-risk investors, hinging on XPro's upcoming Phase II results in early Alzheimer's disease. XPro's unique mechanism targets neuroinflammation without ARIA risk, potentially serving 70% of early AD patients and outperforming current therapies. INMB's short cash runway makes positive XPro data critical for future funding, partnerships, or acquisition; failure could force shareholder dilution.
